| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5658501 | Gastroenterology | 2017 | 24 Pages |
Abstract
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Keywords
DREUSMSTFFDAgFOBTRCTPPVCCERandomized controlled trialfecal immunochemical testguaiac-based fecal occult blood testcolon capsule endoscopypositive predictive valueGrading of Recommendations Assessment, Development and EvaluationRelative riskFood and Drug AdministrationColorectal cancerflexible sigmoidoscopyconfidence intervaldigital rectal examinationGradeFITodds ratioHemoglobinHgbCRC
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex,